Novartis Ag · SIX:NOVN
Novartis — Q3 2023 Earnings Presentation
86 slides from Novartis's earnings presentation, Oct 24, 2023
Slide 1: Q3 2023 Results Investor presentation
Company overview Financial review Conclusions Appendix References Q3 2023 Results Investor presentation 1 Investor Relations │ Q3 2023 Results
Slide 2: Disclaimer
Company overview Financial review Conclusions Appendix References Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “potential,” “expected,” “wil
Slide 3: Company overview
Company Company overview overview Financial review Conclusions Appendix References Vas Narasimhan, M.D. Chief Executive Officer Company overview 3 NOVARTIS Q3 RESULTS | OCTOBER 24, 2023 | NOVARTIS INVESTOR PRESENTATION 3 Investor Relations │ Q3 2023 Results
Slide 4: Novartis delivers strong sales growth, robust margin expansion and raises guidance
Company Company overview overview Financial review Conclusions Appendix References SUMMARY Novartis delivers strong sales growth, robust margin expansion and raises guidance. Successfully spun Sandoz Growth and productivity1 Successful spin-off of Sandoz % cc Completed October 4, 2023 Core margin Co
Slide 5: Strong Q3 growth driven by Kesimpta, Entresto, Kisqali and Pluvicto
Company Company overview overview Financial review Conclusions Appendix References GROWTH Strong Q3 growth driven by performance from Kesimpta®, Entresto®, Kisqali® and Pluvicto®. Cosentyx® returns to growth Q3 sales Sales Growth vs. PY Growth vs. PY USD million USD million cc 657 368 124% 1,485 350
Slide 6: Entresto delivers 31% growth with sales approaching USD 1.5bn
Company Company overview overview Financial review Conclusions Appendix References GROWTH Entresto® delivers 31% growth with sales approaching USD 1.5bn in the quarter Sales evolution US weekly TRx1 USD m, % cc Total prescriptions (000) Strong Q3 momentum Ex-US US 110 § US: robust growth outpacing m
Slide 7: Cosentyx returns to growth; expecting stronger Q4
Company Company overview overview Financial review Conclusions Appendix References GROWTH Cosentyx® returns to growth; expecting stronger Q4 Sales evolution USD m, % cc Q3 performance Ex-US US § US sales (-3%): supported by volume growth, offset by PY base effects § Ex-US sales (+15%): growth in cor
Slide 8: Kesimpta continues strong launch trajectory across regions
Company Company overview overview Financial review Conclusions Appendix References GROWTH Kesimpta® continues strong launch trajectory across regions Sales evolution USD m, % cc US: growing faster than market1,2 Ex-US US § TRx +75% Q3 vs. PY (market +3%) +124%* § NBRx +30% Q3 vs. PY (market +18%) 65
Slide 9: Kisqali sales grew 76% to USD 562m
Company Company overview overview Financial review Conclusions Appendix References GROWTH Kisqali® sales grew 76% to USD 562m, with increasing recognition of its differentiated benefit-risk profile Sales evolution US mBC NBRx share1 Consistent efficacy USD m, % cc Rolling 3 months, % Kisqali Ph3 OS
Slide 10: Kisqali Ph3 NATALEE iDFS 500 event analysis complete
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Kisqali® Ph3 NATALEE iDFS 500 event analysis complete, US submission planned for Q4 2023; file submitted in EU Ph3 NATALEE results as presented at ASCO 20231 ESMO 2023 updates Second interim efficacy analys
Slide 11: Pluvicto grew to USD 256m; supply now unconstrained
Company Company overview overview Financial review Conclusions Appendix References GROWTH Pluvicto® grew to USD 256m; supply now unconstrained, focusing on initiating new patients Sales evolution USD m, % cc Continued progress in Q3 Ex-US US § Growth rates slowed in the quarter given supply challeng
Slide 12: PSMAfore study showed robust efficacy with favorable safety of Pluvicto
Company Company overview overview Financial review Conclusions Appendix References INNOVATION PSMAfore study showed robust efficacy with favorable safety of Pluvicto® in PSMA+ mCRPC patients in the pre-taxane setting Robust efficacy Pluvicto® vs. ARPI arm Favorable safety rPFS1 HR 0.41 (0.29, 0.56)
Slide 13: Scemblix sales grew across all regions
Company Company overview overview Financial review Conclusions Appendix References GROWTH Scemblix® sales grew across all regions, demonstrating the high unmet need in CML Sales evolution USD m § Q3 sales reflect continued demand from patients with Ex-US US Ph+ CML-CP resistant or intolerant to 2 or
Slide 14: Leqvio adoption continues to expand steadily
Company Company overview overview Financial review Conclusions Appendix References GROWTH Leqvio® adoption continues to expand steadily Sales evolution USD m US: Building foundation for acceleration Ex-US US Adoption 90 § 3,100 facilities have ordered Leqvio® (+16% vs. Q2) 78 § >55% of business is f
Slide 15: Key 2023 readouts for high-value medicines on track
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Key 2023 readouts for high-value medicines on track Key assets* with submission enabling readouts in 2023 Kisqali® Pluvicto® Iptacopan Ph3 NATALEE trial in adjuvant breast PSMAfore trial in mCRPC (post-ARDT
Slide 16: Submission enabling readouts expected to increase in 2024-2025
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Submission enabling readouts expected to increase in 2024-2025 timeframe Selected key assets* with submission enabling readouts in 2024-2025 Remibrutinib Pluvicto® Pelacarsen CSU mHSPC CVRR Positive readout
Slide 17: Remibrutinib demonstrated benefit in Ph3 CSU trials
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Remibrutinib demonstrated clinically meaningful and statistically significant benefit in Ph3 CSU trials Ph3 REMIX 1 & 2 studies Remibrutinib met ALL primary and secondary endpoints at 12 weeks Remibrutinib
Slide 18: Remibrutinib – opportunity for efficacious oral therapy
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Remibrutinib – opportunity for efficacious oral therapy with fast onset of action1 after antihistamines Remibrutinib, a highly selective oral BTKi WW: 40m CSU patients2; US: ~1.1m treated adults with CSU3 A
Slide 19: Iptacopan is a potential first-in-class oral factor B inhibitor
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Iptacopan is a potential first-in-class, oral, selective factor B inhibitor, targeting complement system proximally via alternative pathway1 US prevalence Indication 2021 2022 2023 2024 2025 2026+ Key updat
Slide 20: Iptacopan proteinuria reduction in Ph3 APPLAUSE-IgAN
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Iptacopan demonstrated clinically meaningful and highly statistically significant proteinuria reduction in Ph3 APPLAUSE-IgAN Ph3 APPLAUSE-IgAN Positive top-line results at pre-specified Biopsy-confirmed pat
Slide 21: Lutathera Ph3 NETTER-2 results
Company Company overview overview Financial review Conclusions Appendix References INNOVATION Lutathera® Ph3 NETTER-2 results highlight the potential for radioligand therapy (RLT) in earlier disease settings Demonstrated clinically meaningful and statistically NETTER-2 supports potential acceleratio
Slide 22: Financial review and 2023 guidance
Company overview Financial review Financial review Conclusions Appendix References Harry Kirsch Chief Financial Officer Financial review and 2023 guidance 22 NOVARTIS Q3 RESULTS | OCTOBER 24, 2023 | NOVARTIS INVESTOR PRESENTATION 22 Investor Relations │ Q3 2023 Results
Slide 23: 2023 performance continues track record of top-line growth and core margin expansion
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE 2023 performance continues our track record of consistent top-line growth and core margin expansion Continuing operations1 performance, numbers restated post-Sandoz spin-off Net sales % growth Core O
Slide 24: Robust top and bottom-line growth during the quarter and YTD
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Robust top and bottom-line growth during the quarter and YTD Change vs. PY Change vs. PY Continuing operations1 Q3 9M USD million 2023 % USD % cc2 2023 % USD % cc2 Net sales 11,782 12 12 34,017 8 10
Slide 25: Significant improvement in core margin for continuing operations
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Significant improvement in core margin for continuing operations Q3 2023 9M 2023 Core operating Core operating Net sales income Core margin¹ Core margin Net sales income Core margin¹ Core margin chan
Slide 26: Raising FY guidance for core operating income
Company overview Financial review Financial review Conclusions Appendix References FINANCIAL PROFILE Raising FY guidance for core operating income Expected, barring unforeseen events; growth vs. PY in cc Novartis (Continuing operations1) Net sales expected to grow Core operating income expected high
Slide 27: Commitment to shareholder value creation
Company overview Financial review Financial review Conclusions Appendix References STRATEGY Novartis maintains strong commitment to shareholder value creation Investing in the business Returning capital to shareholders Investments in organic business Consistently growing annual dividend2 R&D >USD 45
Slide 28: Vas Narasimhan, M.D.
Company overview Financial review Conclusions Conclusions Appendix References Vas Narasimhan, M.D. Chief Executive Officer 28 NOVARTIS Q3 RESULTS | OCTOBER 24, 2023 | NOVARTIS INVESTOR PRESENTATION 28 Investor Relations │ Q3 2023 Results
Slide 29: Delivered a very strong quarter, upgraded FY 2023 guidance
Company overview Financial review Conclusions Conclusions Appendix References Delivered a very strong quarter, upgraded FY 2023 guidance. Maintaining our commitment to shareholder value creation Very strong Q3: sales +12%, core operating income +21% (cc, continuing operations) Growth drivers continu
Slide 30: Novartis Capital Markets Day, focus R&D
Company overview Financial review Conclusions Conclusions Appendix References Novartis Capital Markets Day, focus R&D November 28, 2023 London Key R&D assets will include: Kisqali®, Pluvicto®, Scemblix®, iptacopan, remibrutinib Additionally, a short update on strategy 30 NOVARTIS Q3 RESULTS | OCTOBE
Slide 31: Appendix
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Appendix 31 Investor Relations │ Q3 2023 Results
Slide 32: 2023 expected key events
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION 2023 expected key events H1 2023 H2 2023 Status update – as of end Q3 Regulatory Cosentyx®
Slide 33: Our pipeline projects at a glance
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Our pipeline projects at a glance Phase 1/2 Phase 3 Registration Total Oncology 28 11 2 41
Slide 34: Novartis pipeline in Phase 1
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 1 16 lead indications Lead indication Oncology Immunology Code
Slide 35: Novartis pipeline in Phase 2
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 2 21 lead indications Lead indication Oncology Immunology Code
Slide 36: Novartis pipeline in Phase 3
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in Phase 3 8 lead indications Lead indication Oncology Cardiovascular Co
Slide 37: Novartis pipeline in registration
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis pipeline in registration 1 lead indications Lead indication Oncology Code Name Me
Slide 38: Novartis submission schedule: new molecular entities
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis submission schedule New Molecular Entities: Lead and supplementary indications Ca
Slide 39: Novartis submission schedule: existing brands
Company overview Financial review Conclusions Appendix Appendix References Innovation: Innovation: Pipeline overview Pipeline overview Financial performance Innovation: Clinical trials Abbreviations INNOVATION Novartis submission schedule Supplementary indications for existing brands Cardiovascular
Slide 40: Expected currency impact for full year 2023 and 2024
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE Expected currency impact for full year 2023 and 2024 Currency impact vs. PY %pts, assuming
Slide 41: FY 2023 guidance on other financial KPIs
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE FY 2023 guidance on other financial KPIs Barring unforeseen events; (in cc) Continuing oper
Slide 42: Net debt increased by USD 3.6bn
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial Financial performance performance Innovation: Clinical trials Abbreviations FINANCIAL PROFILE Net debt increased by USD 3.6bn mainly due to dividends and share buybacks, partially offse
Slide 43: Clinical Trials Update
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Clinical Trials Update Includes selected ongoing
Slide 44: Cardiovascular
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cardiovascular 44 Investor Relations │ Q3 2023 Re
Slide 45: iptacopan - CFB inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inhibit
Slide 46: iptacopan - CFB inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor iptacopan - CFB inhibit
Slide 47: Leqvio - siRNA (regulation of LDL-C)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) NCT03705234
Slide 48: Leqvio - siRNA (regulation of LDL-C)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 49: Leqvio - siRNA (regulation of LDL-C)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Leqvio® - siRNA (regulation of LDL-C) Leqvio® - s
Slide 50: pelacarsen - Antisense oligonucleotide targeting Lp(a)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other pelacarsen - Antisense oligonucleotide (ASO) targ
Slide 51: XXB750 - NPR1 agonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other XXB750 - NPR1 agonist NCT05562934 (CXXB750B12201)
Slide 52: Immunology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Immunology 52 Investor Relations │ Q3 2023 Result
Slide 53: Cosentyx - IL-17A inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A i
Slide 54: Cosentyx - IL-17A inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Cosentyx® - IL-17A inhibitor Cosentyx® - IL-17A i
Slide 55: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 56: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 57: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 58: ligelizumab - IgE Inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ligelizumab - IgE Inhibitor NCT04984876 (CQGE031G
Slide 59: LNA043 - ANGPTL3 agonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other LNA043 - ANGPTL3 agonist NCT04864392 ONWARDS (CLN
Slide 60: remibrutinib - BTK inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK i
Slide 61: remibrutinib - BTK inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor NCT05030311 REMIX-1
Slide 62: Neuroscience
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Neuroscience 62 Investor Relations │ Q3 2023 Resu
Slide 63: Mayzent - S1P1,5 receptor modulator
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Mayzent® - S1P1,5 receptor modulator NCT04926818
Slide 64: remibrutinib - BTK inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other remibrutinib - BTK inhibitor remibrutinib - BTK i
Slide 65: Zolgensma - SMN1 gene replacement therapy
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Zolgensma® - SMN1 gene replacement therapy Zolgen
Slide 66: Oncology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Oncology 66 Investor Relations │ Q3 2023 Results
Slide 67: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor ianalumab - BAFF-R i
Slide 68: ianalumab - BAFF-R inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other ianalumab - BAFF-R inhibitor NCT05648968 VAYHIA (
Slide 69: iptacopan - CFB inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other iptacopan - CFB inhibitor NCT04889430 APPELHUS (C
Slide 70: Jakavi - JAK1/2 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Jakavi® - JAK1/2 inhibitor Jakavi® - JAK1/2 inhib
Slide 71: opnurasib - KRAS inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other opnurasib - KRAS inhibitor NCT05132075 KontRASt-0
Slide 72: Pluvicto - Radioligand therapy target PSMA
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Pluvicto® - Radioligand therapy target PSMA Pluvi
Slide 73: Rydapt - Multi-targeted kinase inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Rydapt® - Multi-targeted kinase inhibitor NCT0359
Slide 74: sabatolimab - TIM3 antagonist
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other sabatolimab - TIM3 antagonist sabatolimab - TIM3
Slide 75: Scemblix - BCR-ABL inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Scemblix® - BCR-ABL inhibitor NCT04971226 ASC4FIR
Slide 76: TNO155 - SHP2 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other TNO155 - SHP2 inhibitor NCT03114319 (CTNO155X2101
Slide 77: Other
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Health Other 77 Investor Rel
Slide 78: Ophthalmology
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Ophthal
Slide 79: Beovu - VEGF Inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Ophthalmology Global Health Beovu®
Slide 80: Global Health
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Global Health
Slide 81: Adakveo - P-selectin inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Adakveo® - P-s
Slide 82: cipargamin - PfATP4 inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health cipargamin - P
Slide 83: Coartem - PGH-1 (artemisinin combination therapy)
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health Coartem® - PGH
Slide 84: ganaplacide - Non-artemisinin plasmodium falciparum inhibitor
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Innovation: Clinical trials Clinical trials Abbreviations Cardiovascular Immunology Neuroscience Oncology Other Ophthalmology Global Global Health ganaplacide -
Slide 85: Abbreviations
Company overview Financial review Conclusions Appendix Appendix References Innovation: Pipeline overview Financial performance Innovation: Clinical trials Abbreviations Abbreviations Abbreviations AI Auto-injector IgAN IgA nephropathy AIH Autoimmune hepatitis IPF Idiopathic pulmonary fibrosis aHUS a
Slide 86: References
Company overview Financial review Conclusions Appendix References References References Entresto® 1 IQVIA National Prescription Audit. 2 Approved indications differ by geography. Examples include “indicated to reduce the risk of cardiovascular death and hospitalization for HF in adult patients with